1. Active Ingredient:

• Apremilast: Apremilast is the active pharmaceutical ingredient in Aprezo tablets. It belongs to a class of medications known as phosphodiesterase 4 (PDE4) inhibitors. Apremilast works by inhibiting the activity of PDE4, which leads to decreased production of pro-inflammatory cytokines and increased production of anti-inflammatory cytokines, ultimately reducing inflammation.

2. Indications:

• Psoriasis: Aprezo is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy.
• Psoriatic Arthritis: Aprezo is also indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to previous disease-modifying anti-rheumatic drugs (DMARDs).

3. Dosage:

• The recommended dosage of Aprezo is 30 mg taken orally twice daily.
• Aprezo tablets should be taken with or without food.
• Dosage adjustments may be necessary based on individual patient factors such as renal function or tolerance to the medication.

4. Administration:

• Aprezo tablets should be swallowed whole with water and should not be crushed, split, or chewed.
• It is important to take Aprezo exactly as prescribed by a healthcare professional.

5. Effectiveness:

• Aprezo has been shown to be effective in reducing the signs and symptoms of psoriasis and psoriatic arthritis, as well as improving physical function and quality of life in affected patients.

6. Safety Profile:

• Aprezo is generally well-tolerated, with the most common adverse reactions including diarrhea, nausea, and headache.
• Serious side effects may include depression, weight decrease, and suicidal ideation, although these are rare.
• Patients should be monitored for signs of depression and suicidal thoughts while taking Aprezo.

7. Contraindications:

• Aprezo is contraindicated in patients with known hypersensitivity to apremilast or any of the excipients in the formulation.
• It should not be used in patients with severe renal impairment or end-stage renal disease requiring dialysis.

8. Precautions:

• Aprezo should be used with caution in patients with a history of depression or suicidal thoughts.
• It should be avoided in pregnant or breastfeeding women unless the potential benefits outweigh the risks.

9. Follow-Up Care:

• Patients receiving Aprezo therapy should undergo regular monitoring by a healthcare professional to assess treatment response, monitor for adverse reactions, and adjust dosage as needed.

Aprezo (Apremilast 30 mg Tablets) represents a valuable treatment option for patients with moderate to severe plaque psoriasis and active psoriatic arthritis. It offers the convenience of oral administration and has demonstrated efficacy in improving symptoms and quality of life in affected individuals. Treatment decisions should be made in consultation with a qualified healthcare professional, considering the individual patient’s medical history, disease severity, and treatment goals.